tbuckley/cabot-search huggingface dataset:
Digital microbiology
Authors: A. Egli, J. Schrenzel, G. Greub
Journal: Clinical Microbiology and Infection (2020)

Digitalization and artificial intelligence have an important impact on the way microbiology laboratories will work in the near future. Opportunities and challenges lie ahead to digitalize the microbiological workflows. Making efficient use of big data, machine learning, and artificial intelligence in clinical microbiology requires a profound understanding of data handling aspects.This review article summarizes the most important concepts of digital microbiology. The article gives microbiologists, clinicians and data scientists a viewpoint and practical examples along the diagnostic process.We used peer-reviewed literature identified by a PubMed search for digitalization, machine learning, artificial intelligence and microbiology.We describe the opportunities and challenges of digitalization in microbiological diagnostic processes with various examples. We also provide in this context key aspects of data structure and interoperability, as well as legal aspects. Finally, we outline the way for applications in a modern microbiology laboratory.We predict that digitalization and the usage of machine learning will have a profound impact on the daily routine of laboratory staff. Along the analytical process, the most important steps should be identified, where digital technologies can be applied and provide a benefit. The education of all staff involved should be adapted to prepare for the advances in digital microbiology.
Prediction of coronary heart disease in African-Americans and whites using multiple-risk-factor assessment equations Herbert J. Marx, Henry F. C. Weil, Thomas A. Pearson, Edward F. Philbin, Tara A. Erb, Paul L. Jenkins, Charles K. Francis, Roberta G. Reed. Mary Imogene Bassett Hospital, Cooperstown, NY, Harlem Hospital, New York City, NY
Journal: Journal of the American College of Cardiology (2001)
The Exchange
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The effect of lesion length on FFR: A study using 3D-IVUS Misao Nakada, Tadanori Aizawa, Hiroshi Sato, Ken Ogasawara, Hajime Kirigaya Kazuyuki Nagashima, Hajime Fujimoto, Yuji Oikawa, Kimihiko Ishimura, Long-Tai Fu, Hiroshi Watanabe. The Cardiovascular Institute, Tokyo, Japan
Journal: Journal of the American College of Cardiology (2001)
Abstract 290: Fibroblast Growth Factor 21 After Out-of-Hospital Cardiac Arrest
Authors: Pirkka T Pekkarinen, Markus B Skrifvars, Pekka Jakkula, Ville Lievonen, Laura Albrecht, Pekka Loisa, Marjaana Tiainen, Ville Pettilä, Matti Reinikainen, Johanna Hästbacka
Journal: Circulation (2018)

Introduction: Fibroblast growth factor (FGF) 21 is a novel marker of mitochondrial and cellular stress. Due to the pivotal role of mitochondria in oxidative metabolism and oxidative stress we tested the hypothesis that FGF 21 would reflect the severity of hypoxia-reperfusion injury after cardiac arrest. Methods: We measured serum concentration of FGF 21 upon ICU admission and 24, 48 and 72 hours after out-of hospital cardiac arrest (OHCA) in 112 patients. All patients had ventricular fibrillation/tachycardia (VF/VT) as initial rhythm and received targeted temperature management (TTM) of 33 or 36 °C for 24 hours. We defined 6-month Cerebral Performance Category (CPC) 1-2 as good and 3-5 as poor neurologic outcome. We used samples from 40 age- and gender-matched non-critically ill emergency room patients as controls. Group differences were assessed with the Mann Whitney U test and temporal differences with Friedman’s ANOVA and Wilcoxon signed ranks test. Results: The median (inter-quartile range, IQR) FGF 21 concentration at ICU admission was 790 (370-1600) pg/ml and the peak value was 1200 (460-2500) pg/ml at 48 hours. Compared to the ICU admission values, the concentrations in control samples [250 (94-910) pg/ml] were significantly lower (P &lt; 0.001). The ICU admission FGF 21 levels were higher in patients with poor neurologic outcome (P = 0.04) and they correlated weakly with the time from collapse to return of spontaneous circulation (Spearman’s rho 0.23). Serum FGF 21 levels changed over time (P &lt; 0.001). Figure 1 presents serum FGF 21 median levels with IQR (box) and 10-90 percentiles (whiskers). Conclusion: Patients after OHCA have elevated FGF 21 levels after successful resuscitation. Higher ICU admission FGF 21 levels associate with poor 6-month neurologic outcome.
Phenome-Wide Association Studies
Authors: Lisa Bastarache, Joshua C. Denny, Dan M. Roden
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pain among older adults diagnosed with gastrointestinal (GI) malignancies: Results from the cancer and aging resilience evaluation (CARE) registry.
Authors: Mustafa Al Obaidi, Sarah Kosmicki, Christian Harmon, Darryl Alan Outlaw, Olumide B. Gbolahan, Moh'd M. Khushman, Smita Bhatia, Smith Giri, Grant Richard Williams
Journal: Journal of Clinical Oncology (2022)

82 Background: The impact of pain on functional status and neuropsychological disorders among older adults with cancer is relevant, yet poorly understood. We sought to identify the prevalence of pain at diagnosis in older adults with GI malignancies and evaluate the association between pain and functional status limitations, cognition, and mental health issues. Methods: This study included patients diagnosed with cancer at age ≥60 years and enrolled in the CARE Registry at the University of Alabama at Birmingham (UAB). Patients completed a patient-reported geriatric assessment at their initial visit with a medical oncologist. Patients rated pain on a numeric scale from 0-10. We employed the literature-based cut off for moderate-severe pain of ≥4. Logistic regression modeling was used to determine the association between moderate/severe pain and functional status, falls, cognition, and depression/anxiety. We adjusted the models for sex, race, education, race/ethnicity, marital status, cancer type, and cancer stage. Results: Our cohort included 714 older adults. Median age at diagnosis was 70y (range 60-96) and 59% were male. Median time between diagnosis and study participation was 37 days. Most prevalent diagnoses included colorectal (27.9%), pancreatic (18%), hepatobiliary (11.5%) and gastroesophageal (6.4%) cancers. Overall, 53.1% of the participants reported none/mild (0-3) pain, 25.6% reported moderate (4-7) pain, and 21.4% reported severe (8-10) pain. In univariate analyses, Black patients, lower education, disabled employment, and pancreatic cancer was associated with moderate/severe pain. After multivariate adjusting for covariates, participants with moderate/severe pain were more likely to report limitations in instrumental activities of daily living (adjusted Odds Ratio [aOR] 4.3, 95% confidence interval [CI] 3.1-6.1, p &lt;.001), limitations in activities of daily living (aOR 3.2, 95% CI 2.0-5.1, p &lt;.001), falls (aOR 2.4, 95% CI 1.6-3.6, p &lt;.001), cognitive complaints (aOR 2.9, 95% CI 1.4-6.0, p &lt;.004), anxiety (aOR 2.2, 95% CI 1.4-3.4, p &lt; 0.01), and depression (aOR 3.7, 95% CI 2.2-6.5, p &lt;.001). Conclusions: Pain is common amongst older adults with GI cancers and is associated with functional status limitations, falls, cognitive complaints, and depression/anxiety. Strategies to reduce pain and/or minimize its potential impact on function and mental health warrant future research.
Improved Observational Method for Studying Therapeutic Efficacy
Authors: Ralph I. Horwitz
Journal: JAMA (1981)

Criteria for patient eligibility in a randomized clinical trial can be used to improve the design of observational case-control studies. The new strategy has been illustrated in a case-control investigation of whether lidocaine prophylaxis prevents death in patients with acute myocardial infarction. From among patients hospitalized with myocardial infarction in a special care unit during 1974 to 1978, there were 151 fatalities (cases) and 151 survivors (controls) selected for study. After removal of the ineligible cases and controls, lidocaine prophylaxis was found to have no effect on death from pump failure or nonarrhythmic causes, but was significantly protective against death from ventricular arrhythmias, particularly in patients with congestive heart failure. If confirmed by rigorously designed longitudinal studies, the improved case-control technique could serve as a useful "screening" device to assess the efficacy of medical or surgical treatments that cannot be tested with randomized clinical trials. (<i>JAMA</i>1981;246:2455-2459)
Error in Table 1
Journal: JAMA Network Open (2021)

Aristithes G. Doumouras, MD, MPH; Yung Lee, MD; J. Michael Paterson, MSc; Hertzel C. Gerstein, MD, MSc; Baiju R. Shah, MD, PhD; Branavan Sivapathasundaram, MPH; Jean-Eric Tarride, PhD; Mehran Anvari, MD, PhD; Dennis Hong, MD, MSc
Medicolegal.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Relationship between the left atrial and left ventricular pressures and pulmonary venous flow velocities in animals with and without mitral regurgitation Dene Wesley Daugherty, Michael Jones, Takahiro Shiota, Dag Teien, Fabrice Bauer, Marta Sitges, Jian Xin Qin, Hiroyuki Tsujino, Arthur D. Zetts, Julio A. Panza, James D. Thomas. The Cleveland Clinic Foundation, Cleveland, OH, The National Institutes of Health, Bethesda, MD
Journal: Journal of the American College of Cardiology (2001)
Superfluous Spectacles.
Authors: James A. Lydston
Journal: JAMA (1894)

<h3>To the Editor:</h3> —Replying to the comments in your editorial columns Feb.3, 1894, under the caption of "Superfluous Spectacles," which is evidently designed to stimulate a so-called "healthy reaction against the one-sidedness which has of late years permeated American ophthalmological literature," permit us to say that we were not aware that any very disastrous results had followed the application of glasses in any and all cases in which they were indicated, and indeed in the majority of cases great benefit has ensued. So firmly are we of this belief that we would respond to the query, "Does every optical defect need correction, and is every case of painful vision curable by glasses?" Yes; every optical defect sufficient in degree to give rise to the disagreeable train of symptoms called asthenopia should be corrected and in all cases of refractive error, pure and simple, accompanied by painful vision we can, with
Subclavian Steal
Authors: CARL L. WILLIAMS, STEWART M. SCOTT, TIMOTHY TAKARO
Journal: Circulation (1963)

Five patients with subclavian artery stenosis, reversed vertebral artery blood flow, and basilar arterial insufficiency have been described. Four patients were successfully treated by arterial reconstruction. Serial angiography demonstrated in each case a stenosis of the subclavian artery proximal to the origin of the vertebral artery, with delayed retrograde flow through this vertebral artery to the subclavian artery distally.
Pulmonary Pathophysiology
Authors: Neil S. Cherniack
Journal: Annals of Internal Medicine (1999)

Medical Writings: Book Notes7 September 1999Pulmonary PathophysiologyNeil S. Cherniack, MDNeil S. Cherniack, MDUMDNJ-New Jersey Medical School, Newark, New Jersey. (Cherniack)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-5-199909070-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Ali J, Summer WR, Levitzky MG; eds. 347 pages. New York: McGraw-Hill; 1999. $32.50. ISBN 0070621705. Order phone 800-262-4729.Field of medicine: Respiratory physiology and disease.Format: Softcover book.Audience: Students, residents, and fellows in internal medicine, pediatrics, anesthesia, pulmonary medicine, and critical care. Nurse practitioners may find this book useful.Purpose: To “bridge the gap between multi-volume reference texts and review monographs dealing with pulmonary pathophysiology.”Content: This is a companion to Levitzky's Pulmonary Physiology (McGraw-Hill, 1999). The first part covers symptoms in a problem-based format, with excellent discussions of the pathophysiology underlying such symptoms as dyspnea, cough, and ... Author, Article, and Disclosure InformationAffiliations: UMDNJ-New Jersey Medical School, Newark, New Jersey. (Cherniack) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 September 1999Volume 131, Issue 5Page: 399KeywordsCritical careIschemiaLungsNursesPediatricsPulmonary diseasesPulmonary medicineRespiratory physiologySleepSoftware tools ePublished: 15 August 2000 Issue Published: 7 September 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
TREASURERS OF THE ASSOCIATION.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NON-A, NON-B HEPATITIS AFTER INTRAVENOUS GAMMAGLOBULIN
Authors: A.D.B. Webster, A.M.L. Lever, C. Trepo, O. Hantz, L. Vitvitski, HansD. Ochs, SusannaH. Fischer, FrankS. Virant, MartinL. Lee, Samia Mankarious, HenryS. Kingdon, RalphJ. Wedgwood
Journal: The Lancet (1986)
Downstaging radiotherapy and surgical transformation for initially unresectable or borderline resectable hepatocellular carcinoma: A phase II study.
Authors: Ting-Shi Su, Wen-Feng Gong, Chang Zhao, Shi-Xiong Liang, Le-Qun Li, Bang-De Xiang
Journal: Journal of Clinical Oncology (2022)

442 Background: Downstaging radiotherapy provide patients with initially unresectable or borderline resectable hepatocellular carcinoma (HCC) a chance to receive conversion curative resection. This study intended to prospectively evaluate the efficacy and toxicities of downstaging radiotherapy for HCC with macroscopic vascular invasion. Methods: From March 2018 to May 2020, 30 HCC patients with macroscopic vascular invasion were prospectively treated with transcatheter arterial chemoembolization combined with radiotherapy (n = 24) or radiotherapy alone (n = 6). The primary study endpoint was overall survival (OS). The secondary study endpoints were progression free survival (PFS), downstaging success rate, and surgical conversion rate. Adverse events were assessed. Results: The follow-up time of the entire cohort was 24 months. The median OS of the entire cohort was 22.0 months, 12-, and 24- months OS was 60.0% and 47.8%, respectively. The median PFS was 13.0 months, 12-, and 24-months PFS was 53.3% and 27.0%, respectively. During downstaging window phase within 3-6 months, 22 patients were evaluated as downstaging success by clinical imaging. Among them, 9 patients underwent R0 radical hepatectomy and 13 patients refused surgical treatment, yielding a downstaging success rate of 73.3% (22/30 patients) and a surgical conversion rate of 30.0% (9/30 patients). Of the patients who underwent surgery, 4 patients (44.4%) experienced ≥ grade 4 postoperative complications, including 2 (22.2%) with gastrointestinal bleeding and 2 (22.2%) with bile leakage. Conclusions: For unresectable or borderline resectable HCCs complicated with macroscopic vascular invasion, high-dose radiotherapy-based treatment provided favorable downstaging efficacy, surgical conversion rate, and survival outcomes. Clinical trial information: ChiCTR1800015350.
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
Authors: Satya Das, Aman Chauhan, Liping Du, Katharine E. Thomas, Aasems Jacob, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana B. Cardin, Kristen K. Ciombor, Laura W. Goff, Marques Bradshaw, Dominique Delbeke, Martin Sandler, Robert A. Ramirez, Jordan Berlin
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Despite the benefit of peptide receptor radionuclide therapy (PRRT) for patients with well-differentiated neuroendocrine tumors (WD NETs), no clinical metric to anticipate benefit from the therapy for individual patients has been previously defined. <h3>Objective</h3> To assess whether the prognostic ability of the clinical score (CS) could be validated in an external cohort of patients with WD NETs. <h3>Design, Setting, and Participants</h3> This multicenter cohort study's analysis included patients with WD NETs who were under consideration for peptide receptor radionuclide therapy (PRRT) with lutetium-177 (<sup>177</sup>Lu)-dotatate between March 1, 2016, and March 17, 2020. The original cohort included patients from Vanderbilt-Ingram Cancer Center. The validation cohort included patients from Ochsner Medical Center, Markey Cancer Center, and Rush Medical Center. Patients with paragangliomas, pheochromocytomas and neuroblastomas were excluded. Statistical analysis was performed from June to November 2021. <h3>Exposures</h3> PRRT with<sup>177</sup>Lu-dotatate or alternate therapies such as everolimus, sunitinib, or capecitabine plus temozolomide. <h3>Main Outcomes and Measures</h3> The primary outcome was progression-free survival (PFS) and was estimated by the Kaplan-Meier method; a Cox proportional-hazards model adjusting for primary tumor site, tumor grade, and number of PRRT doses administered was used to analyze association between CS and outcomes. <h3>Results</h3> A total of 126 patients (median age [IQR] age: 63.6 [52.9-70.7] years; 64 male individuals) were included in the validation cohort, and the combined cohort (validation and original cohorts combined) had a total of 248 patients (median [IQR] patient age: 63.3 [53.3-70.3] years; 126 male individuals). In the validation cohort, on multivariable analysis, for each 2-point increase in CS, PFS decreased significantly (hazard ratio, 2.61; 95% CI, 1.64-4.16). After finding an association of the CS with PFS in the validation cohort, the original and validation cohorts were combined into the cohort for this analysis. On multivariable analysis, for each 2-point increase in CS, PFS decreased significantly (hazard ratio, 2.52; 95% CI, 1.89-3.36). <h3>Conclusions and Relevance</h3> Increases in CS were associated with worsening PFS in the validation cohort, validating findings from the original cohort. These findings suggest that the CS, to our knowledge, represents the first clinical metric to estimate anticipated benefit from PRRT for patients with WD NETs and may be a clinical tool for patients being considered for PRRT.